| "Borrelomycetales" Turner 1935| "Mollicutales" Edward 1955| "Paramycetales" Sabin 1941| "Pleuropneumoniales" Tulasne and Brisou 1955| Borrelomycetales| Mollicutales| Mycoplasmas| Mycoplasmatales| Mycoplasmatales Freundt 1955 (Approved Lists 1980) emend. Tully et al. 1993| Paramycetales| Pleuropneumoniales| The Mycoplasmas
Human infections: Mycoplasmas are associated with various human infections, including respiratory tract infections, genital tract infections, and systemic infections. Mycoplasma pneumoniae, for example, is a common cause of atypical pneumonia (walking pneumonia) and respiratory tract infections in humans, particularly in children and young adults.
Genital tract infections: Mycoplasmas can cause infections in the genital tract, including urethritis, cervicitis, pelvic inflammatory disease (PID), and sexually transmitted infections (STIs) such as Mycoplasma genitalium. These infections can lead to symptoms such as genital discharge, pelvic pain, and discomfort during urination.
Neonatal infections: Mycoplasmas can be transmitted from mother to baby during childbirth and can cause infections in newborns, including pneumonia, sepsis, and meningitis. Neonatal infections with Mycoplasma species can be serious and may require prompt medical treatment.
Joint infections: Mycoplasma species have been implicated in joint infections, particularly in children and young adults. Mycoplasma arthritis is characterized by joint pain, swelling, and inflammation and may occur in conjunction with respiratory or genital tract infections.
Autoimmune diseases: Some studies have suggested a possible association between Mycoplasma infections and autoimmune diseases, such as rheumatoid arthritis and Guillain-BarrΓ© syndrome. It is hypothesized that mycoplasma infections may trigger or exacerbate autoimmune responses in susceptible individuals.
Chronic diseases: Mycoplasmas have been implicated in the pathogenesis of chronic diseases, including chronic fatigue syndrome (CFS) and fibromyalgia. While the exact role of mycoplasmas in these conditions is not fully understood, some studies have reported associations between mycoplasma infections and symptom severity in affected individuals.
Antibiotic resistance: Mycoplasma species are inherently resistant to many antibiotics due to their lack of a cell wall and limited metabolic pathways. This can pose challenges for the treatment of mycoplasma infections and may require the use of specific antibiotics, such as macrolides or fluoroquinolones.
A lot more information is available when you are logged in and raise the display level
Other Sources for more information:
Statistics | NCBI | Data Punk | End Products Produced |
Different labs use different software to read the sample. See this post for more details.
One lab may say you have none, another may say you have a lot! - This may be solely due to the software they are using to estimate.
We deem lab specific values using values from the KM method for each specific lab to be the most reliable.
Lab | Frequency | UD-Low | UD-High | KM Low | KM High | Lab Low | Lab High | Mean | Median | Standard Deviation | Box Plot Low | Box Plot High | KM Percentile Low | KM Percentile High |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Other Labs | 2.12 | 10 | 2090 | 0 | 1128 | 250 | 43 | 448.2 | 0 | 382 | 0 %ile | 100 %ile | ||
biomesight | 78.29 | 0 | 90 | 30 | 130 | 0 | 285 | 88.5 | 60 | 100.1 | 20 | 160 | 8 %ile | 90.8 %ile |
thorne | 100 | 10 | 189 | 0 | 159 | 60.4 | 33 | 50.2 | 11 | 141 | 0 %ile | 100 %ile | ||
thryve | 72.65 | 0 | 68 | 21 | 155 | 0 | 3499 | 212.6 | 54 | 1677 | 2 | 176 | 12.1 %ile | 90.1 %ile |
ubiome | 1.39 | 18 | 10601 | 0 | 7349 | 1215.5 | 221 | 3129.6 | 18 | 10601 | 7.7 %ile | 84.6 %ile |
Source of Ranges | Low Boundary | High Boundary | Low Boundary %age | High Boundary %age |
---|---|---|---|---|
Thorne (20/80%ile) | 8.91 | 25.53 | 0.0009 | 0.0026 |
Lab | Frequency Seen | Average | Standard Deviation | Sample Count | Lab Samples |
---|---|---|---|---|---|
BiomeSight | 84.323 % | 0.009 % | 0.01 % | 2415.0 | 2864 |
BiomeSightRdp | 59.375 % | 0.006 % | 0.011 % | 19.0 | 32 |
bugspeak | 100 % | 0.01 % | % | 1.0 | 1 |
CerbaLab | 66.667 % | 0.004 % | 0.001 % | 2.0 | 3 |
custom | 16.949 % | 0.003 % | 0.003 % | 10.0 | 59 |
es-xenogene | 17.241 % | 0.101 % | 0.058 % | 5.0 | 29 |
Medivere | 71.429 % | 0.004 % | 0.001 % | 5.0 | 7 |
Microba | 7.143 % | 0.129 % | 0.114 % | 2.0 | 28 |
SequentiaBiotech | 27.778 % | 0.027 % | 0.019 % | 10.0 | 36 |
Thorne | 85.227 % | 0.004 % | 0.004 % | 75.0 | 88 |
Thryve | 73.536 % | 0.019 % | 0.15 % | 1017.0 | 1383 |
Tiny | 100 % | 0.001 % | % | 1.0 | 1 |
uBiome | 1.389 % | 0.122 % | 0.313 % | 11.0 | 792 |
Click on Impact for information if high or low levels are causing the impact
Magnitude | Impact | Symptom |
---|
|
And display level must be raised above public.
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.